This post was originally published on this site A combination of ilixadencel plus Sutent (sunitinib) is showing promising efficacy in patients with kidney cancer that has spread to other organs, according to topline data from a Phase 2 trial. Ilixadencel, Immunicum‘s lead candidate for the treatment of different types of solid tumors, is a cancer…
This post was originally published on this site Prolaris, a genetic test developed by Myriad Genetics to help predict the aggressiveness of prostate cancer, can accurately identify prostate cancer patients with low-risk disease who may safely opt for active surveillance, a study found. Among 547 men who choose active surveillance, only two experienced tumor progression…
This post was originally published on this site On Sept. 20, the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) and the European Society of Gynaecological Oncology (ESGO) presented the first World Gynecologic Oncology Day (World GO Day). Spearheaded by ENGAGe, the initiative, set to occur annually, aims to promote collaboration among patient groups, strengthen…
This post was originally published on this site Adding Darzalex (daratumumab) to a combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone — called the VRd combo — increases the proportion of people with multiple myeloma who experience a decrease in tumor burden, a Phase 2 trial shows. The results occurred among newly diagnosed patients eligible…
This post was originally published on this site When given together with Herceptin (trastuzumab) at a fixed dose through an under-the-skin (subcutaneous) injection, Perjeta (pertuzumab) reaches levels in the blood in women with HER2-positive breast cancer that is similar to those seen when the medication is administered intravenously, data from a Phase 3 trial shows.…
This post was originally published on this site For the first time, scientists have found evidence that pain is an independent marker for overall survival in recurrent ovarian cancer, with women with pain living for significantly less time after their diagnosis than those without pain. The survival toll is particularly high for patients with pain…
This post was originally published on this site GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have received prior therapies. The FDA’s Office of Orphan Products Development (OOPD) gives this designation to novel…
This post was originally published on this site In solidarity with cancer patients, including those with lymphoma, thousands of people throughout the U.S. are expected to sport bald caps Oct. 18 as part of an annual effort called “Be Bold, Be Bald!” to raise funds and awareness. The event — held every year on the…
This post was originally published on this site Magrolimab, an experimental antibody developed by Forty Seven, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The designation is given to therapies that show potential to treat serious health conditions, and…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved use of a device, called LiPlaCis DRP, that works to predict response to the next-generation investigational chemotherapy LiPlaCis in a planned Phase 3 clinical trial in people with metastatic breast cancer, Oncology Venture, the company developing both, reports. The FDA is…
